These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

414 related articles for article (PubMed ID: 25548993)

  • 21. IRF4 gene rearrangements define a subgroup of CD30-positive cutaneous T-cell lymphoma: a study of 54 cases.
    Pham-Ledard A; Prochazkova-Carlotti M; Laharanne E; Vergier B; Jouary T; Beylot-Barry M; Merlio JP
    J Invest Dermatol; 2010 Mar; 130(3):816-25. PubMed ID: 19812605
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Complete remission of refractory, ulcerated, primary cutaneous CD30+ anaplastic large cell lymphoma following brentuximab vedotin therapy.
    Patsinakidis N; Kreuter A; Moritz RK; Stücker M; Altmeyer P; Möllenhoff K
    Acta Derm Venereol; 2015 Feb; 95(2):233-4. PubMed ID: 24733422
    [No Abstract]   [Full Text] [Related]  

  • 23. Cytologic evaluation of lymphadenopathy associated with mycosis fungoides and Sezary syndrome: role of immunophenotypic and molecular ancillary studies.
    Pai RK; Mullins FM; Kim YH; Kong CS
    Cancer; 2008 Oct; 114(5):323-32. PubMed ID: 18798522
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Detection of clonal T-cell receptor gamma gene rearrangements with the use of the polymerase chain reaction in cutaneous lesions of mycosis fungoides and Sézary syndrome.
    Bachelez H; Bioul L; Flageul B; Baccard M; Moulonguet-Michau I; Verola O; Morel P; Dubertret L; Sigaux F
    Arch Dermatol; 1995 Sep; 131(9):1027-31. PubMed ID: 7661604
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CD25+ folliculotropic Sézary syndrome with CD30+ large cell transformation.
    Jang MS; Kang DY; Han SH; Park JB; Kim ST; Suh KS
    Australas J Dermatol; 2014 Feb; 55(1):e4-8. PubMed ID: 23190349
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Localized perineal cutaneous nodules: a case of recurrent systemic anaplastic large-cell lymphoma.
    Hernandez C; Puangsuvan SN; Peterson A; Robinson JK
    Clin Exp Dermatol; 2009 Dec; 34(8):e722-5. PubMed ID: 20055841
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Reduction of regulatory T cells by Mogamulizumab, a defucosylated anti-CC chemokine receptor 4 antibody, in patients with aggressive/refractory mycosis fungoides and Sézary syndrome.
    Ni X; Jorgensen JL; Goswami M; Challagundla P; Decker WK; Kim YH; Duvic MA
    Clin Cancer Res; 2015 Jan; 21(2):274-85. PubMed ID: 25376389
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Durable clinical, cytogenetic, and molecular remissions after allogeneic hematopoietic cell transplantation for refractory Sezary syndrome and mycosis fungoides.
    Molina A; Zain J; Arber DA; Angelopolou M; O'Donnell M; Murata-Collins J; Forman SJ; Nademanee A
    J Clin Oncol; 2005 Sep; 23(25):6163-71. PubMed ID: 16135483
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Localization of clonal T cells to the epidermis in cutaneous T-cell lymphoma.
    Fivenson DP; Hanson CA; Nickoloff BJ
    J Am Acad Dermatol; 1994 Nov; 31(5 Pt 1):717-23. PubMed ID: 7929915
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A case of mycosis fungoides after CD30 positive anaplastic large cell lymphoma.
    Lee MW; Chi DH; Choi JH; Sung KJ; Moon KC; Koh JK
    J Dermatol; 2000 Jul; 27(7):458-61. PubMed ID: 10935344
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Diagnostic and prognostic evaluation of phenotypic markers TRAF1, MUM1, BCL2 and CD15 in cutaneous CD30-positive lymphoproliferative disorders.
    Benner MF; Jansen PM; Meijer CJ; Willemze R
    Br J Dermatol; 2009 Jul; 161(1):121-7. PubMed ID: 19416236
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Clinicopathological differential diagnosis of mycosis fungoides/Sézary syndrome from the cutaneous type of adult T-cell leukemia/lymphoma].
    Johno M; Ono T
    Nihon Rinsho; 2000 Mar; 58(3):660-4. PubMed ID: 10741142
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Transformed mycosis fungoides: clinicopathological features and outcome.
    Barberio E; Thomas L; Skowron F; Balme B; Dalle S
    Br J Dermatol; 2007 Aug; 157(2):284-9. PubMed ID: 17573879
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Differential patterns of CXCR3, CCR3, and CCR10 expression in mycosis fungoides, Sezary syndrome and CD30(+) lymphoproliferative disorders: immunohistochemical study of 43 samples.
    Suga H; Sugaya M; Miyagaki T; Ohmatsu H; Fujita H; Asano Y; Tada Y; Kadono T; Sato S
    J Dermatol Sci; 2011 Nov; 64(2):142-4. PubMed ID: 21868202
    [No Abstract]   [Full Text] [Related]  

  • 35. Clinicopathologic and immunologic features associated with transformation of mycosis fungoides to large-cell lymphoma.
    Cerroni L; Rieger E; Hödl S; Kerl H
    Am J Surg Pathol; 1992 Jun; 16(6):543-52. PubMed ID: 1599034
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CD30+ neoplasms of the skin.
    Duvic M
    Curr Hematol Malig Rep; 2011 Dec; 6(4):245-50. PubMed ID: 21850406
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Upregulation of inhibitory signaling receptor programmed death marker-1 (PD-1) in disease evolution from cutaneous lymphoid dyscrasias to mycosis fungoides and Sezary's syndrome.
    Nguyen GH; Olson LC; Magro CM
    Ann Diagn Pathol; 2017 Jun; 28():54-59. PubMed ID: 28648940
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Acquisition of CD30 and CD15 accompanied with simultaneous loss of all pan-T-cell antigens in a case of histological transformation of mycosis fungoides with involvement of regional lymph node: an immunophenotypic alteration resembling classical Hodgkin lymphoma.
    Reddi DM; Sebastian S; Wang E
    Am J Dermatopathol; 2015 Mar; 37(3):249-53. PubMed ID: 23612034
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Toll-like receptors 2, 4 and 9 expression in cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome).
    Jarrousse V; Quereux G; Marques-Briand S; Knol AC; Khammari A; Dreno B
    Eur J Dermatol; 2006; 16(6):636-41. PubMed ID: 17229603
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Practical Management of CD30⁺ Lymphoproliferative Disorders.
    Hughey LC
    Dermatol Clin; 2015 Oct; 33(4):819-33. PubMed ID: 26433852
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.